Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Net Income

Bottom-line profit after all expenses, interest, and taxes.

Pulse Biosciences, Inc.NASDAQ: PLSE

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income remains negative

Q2 FY2026 net income was -$24.66M, compared with -$19.17M a year earlier. Trailing-twelve-month net income was -$80.06M.

Context

  • Net income amounted to 20794.6% of revenue in FY2025.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$73.03M (-0.3%) for the fiscal year ending Dec 2026, a step up from the -35.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$24.66M-32.7% QoQ
Last fiscal yearDec 2025
-$72.78M-35.8% YoY
LTMJun 2026
-$80.06M-17.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.6%-14.8%+13.8 pp
1 year-35.8%-0.3%+35.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(72.78M) USD
Year-over-year change
-35.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.7% is the 5th highest of 11, against a peer median of -43.5%.
  • Net income amounts to 6755.8% of revenue for PLSE, versus a peer median of 116.6%.
PLSE Competitors
Net Income for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LFMDLifeMD, Inc.LTM Mar 2026-$16.25M USD-58.5%—7.4%
STAASTAAR Surgical CompanyLTM Apr 2026-$21.03M USD+70.4%—7.2%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$29.91M USD+73.9%—1570.9%
BBNXBeta Bionics, Inc.LTM Mar 2026-$66.44M USD+6.4%—60.3%
PLSEPulse Biosciences, Inc.LTM Jun 2026-$80.06M USD-17.7%—6755.8%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026-$144.83M USD-72.3%—173.0%
NKTRNektar TherapeuticsLTM Jun 2026-$157.13M USD-28.5%—287.8%
NVCRNovoCure LimitedLTM Mar 2026-$173.05M USD-5.4%—25.7%
OPKOPKO Health, Inc.LTM Mar 2026-$212.92M USD-445.9%—36.6%
IMTXImmatics N.V.LTM Mar 2026-€214.41M EUR-893.4%—574.9%
ATAIAtai Beckley Inc.LTM Jun 2026-$668.19M USD-459.6%—14938.4%
Peer median (excluding PLSE) —-43.5%—116.6%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.42M700K00350K
Cost of Revenue1.97M11.94M1.21M01.61M
Gross Profit(550K)(11.24M)(1.21M)0(1.26M)
Gross Margin-38.8%-1606.3%——-360.0%
Research & Development28.64M20.84M27.8M32.34M44.72M
Selling, General & Admin33.82M25.97M15.78M23.92M32.03M
Operating Expenses62.46M46.81M42.37M56.26M75.68M
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
EBITDA(62.51M)(57.15M)(39.9M)(52.41M)(71.71M)
EBITDA Margin-4408.6%-8164.3%——-20488.6%
Operating Income(63.01M)(58.06M)(43.57M)(56.26M)(76.94M)
Operating Margin-4443.9%-8293.9%——-21982.6%
Interest Income002.46M2.67M4.21M
Interest Expense646K448K1.1M00
Other Income / Expenses(646K)(448K)1.36M2.67M4.16M
Income Before Tax(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Pre-Tax Margin-4489.4%-8357.9%——-20794.6%
Income Tax Expense00000
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Net Margin-4489.4%-8357.9%——-20794.6%
EPS (Basic)(2.28)(1.72)(0.88)(0.92)(1.08)
EPS (Diluted)(2.28)(1.72)(0.88)(0.92)(1.08)
Weighted Avg Shares27.96M33.94M48.04M58.4M67.4M
Weighted Avg Shares (Diluted)27.96M33.94M48.04M58.4M67.4M

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.